Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 15/20 | 0.45 |
| ▸ | NPY1R | P25929 | 9/20 | 0.45 |
| ▸ | NPY5R | Q15761 | 8/20 | 0.45 |
| ▸ | NPY2R | P49146 | 5/20 | 0.45 |
| ▸ | ANPEP | P15144 | 3/20 | 0.38 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.38 |
| ▸ | DNPEP | Q9ULA0 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11012210 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RANPEP | |
| SCHEMBL4087611 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RANPEP | |
| SCHEMBL28719983 | 1.00 | NPY4R (0.45) | NPY4RNPY1RNPY5RNPY2RANPEP | |
| SCHEMBL16497315 | 0.94 | NPY4R (0.52) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11593401 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11593408 | 0.92 | NPY4R (0.46) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11783082 | 0.90 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL11783099 | 0.90 | NPY4R (0.47) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL16468686 | 0.89 | NPY4R (0.50) | NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL2183420 | 0.88 | NPY4R (0.41) | NPY4RNPY1RNPY5RNPY2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109438363-B | Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt | 陕西慧康生物科技有限责任公司 | 2022-04-29 | — | — | CN | claimed |
| CN-109438363-A | A kind of liquid phase high-purity scale synthetic method of ring (leucyl-arginyl) dipeptides salt | 陕西慧康生物科技有限责任公司 | 2019-03-08 | — | — | CN | claimed |
| US-4505852-A | 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors | ENZYME SYSTEMS PRODUCTS (US) | 1985-03-19 | — | — | US | claimed |
| CN-109438363-B | Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt | 陕西慧康生物科技有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-109438363-B | Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt | 陕西慧康生物科技有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-109438363-B | Liquid-phase high-purity large-scale synthesis method of cyclic (leucyl-arginyl) dipeptide salt | 陕西慧康生物科技有限责任公司 | 2022-04-29 | — | — | CN | disclosed |
| CN-113754718-A | Liquid phase synthesis method of tripeptide leucyl-arginyl-tryptophan | 湖北泓肽生物科技有限公司 | 2021-12-07 | — | — | CN | disclosed |
| CN-109438363-A | A kind of liquid phase high-purity scale synthetic method of ring (leucyl-arginyl) dipeptides salt | 陕西慧康生物科技有限责任公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109438363-A | A kind of liquid phase high-purity scale synthetic method of ring (leucyl-arginyl) dipeptides salt | 陕西慧康生物科技有限责任公司 | 2019-03-08 | — | — | CN | disclosed |
| CN-109438363-A | A kind of liquid phase high-purity scale synthetic method of ring (leucyl-arginyl) dipeptides salt | 陕西慧康生物科技有限责任公司 | 2019-03-08 | — | — | CN | disclosed |
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | MCKEARN JOHN P (US) | 2005-02-17 | — | — | US | disclosed |
| US-4505852-A | 7-Amino-4-trifluoromethylquinolone derived substrates and method for determining enzymes and inhibitors | ENZYME SYSTEMS PRODUCTS (US) | 1985-03-19 | — | — | US | disclosed |
| US-4111923-A | LUTEINIZING HORMONE RELEASING FACTOR ANTAGONISTS | PARKE, DAVIS & COMPANY (US) | 1978-09-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050037090-A1 | Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent | PTGS2, PTGES2, PTGS1 | NPY4R 3453/4885NPY1R 2901/4885NPY5R 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.